histor
live
attenu
replic
vaccin
rather
inactiv
prepar
provid
effect
protect
viral
infect
diseas
partial
list
vaccin
includ
measl
mump
rubella
polio
vaccinia
yellow
fever
notabl
vaccin
elicit
essenti
lifelong
protect
immun
contrast
immun
induc
inactiv
subunit
vaccin
gener
limit
durat
key
factor
pursuit
latter
approach
safeti
concern
aris
possibl
diseas
induct
vaccin
individu
particularli
immun
compromis
also
spread
vaccin
viru
popul
issu
perhap
evid
effort
develop
vaccin
hiv
target
popul
like
includ
individu
alreadi
infect
hiv
perhap
immun
suppress
result
infect
yet
nowher
urgenc
vaccin
develop
greater
aid
field
chapter
replic
nonrepl
viral
vector
discuss
focu
larg
aid
vaccin
research
spectrum
type
vector
uniqu
advantag
disadvantag
develop
review
sever
categori
illustr
issu
face
vector
select
viral
vector
replic
nonrepl
form
avail
includ
adenovirus
poxvirus
vector
design
primarili
replicationdefect
includ
adenoassoci
viru
alphaviru
herpesviru
replic
vector
includ
measl
viru
vesicular
stomat
viru
vector
base
success
vaccin
less
heavili
exploit
cover
exampl
polioviru
yellow
fever
viru
vaccin
replicationcompet
elicit
lifelong
persist
immun
yet
vector
exhibit
genet
instabl
also
small
insert
capac
limit
interest
vaccin
develop
featur
variou
viral
vector
recent
result
follow
use
first
review
follow
consider
issu
face
vector
select
tabl
list
properti
vector
cover
adenovirus
ad
among
heavili
exploit
vector
vaccin
develop
virolog
molecular
biolog
doublestrand
dna
viru
heavili
investig
year
part
gene
therapi
applic
provid
invalu
knowledg
base
develop
vaccin
arena
sever
ad
featur
particularli
attract
vaccin
use
includ
infect
divid
nondivid
cell
high
level
transgen
express
abil
grow
high
titer
vitro
lack
integr
host
genom
physic
genet
stabil
importantli
ad
infect
dendrit
cell
upregul
costimulatori
molecul
elicit
cytokin
chemokin
respons
thu
effect
present
antigen
immun
system
elicit
potent
immun
respons
ad
target
epitheli
cell
prime
candid
elicit
mucos
well
system
immun
ad
vector
design
broad
spectrum
vaccin
applic
includ
hiv
siv
also
multipl
dna
singl
doublestrand
rna
virus
ad
render
replic
defect
delet
region
gene
essenti
replic
vector
gener
nonessenti
region
delet
well
order
creat
space
foreign
gene
express
cassett
insert
transgen
control
exogen
promot
extens
develop
nonrepl
ad
vector
one
first
viral
vector
appli
hiv
vaccin
research
potenti
elicit
strong
cellular
immun
respons
insert
gene
quickli
notic
recognit
import
vector
potenti
vaccin
candid
establish
find
better
protect
experiment
infect
nonhuman
primat
chimer
sivhiv
viru
shiv
compar
anim
immun
plasmid
dna
mva
recombin
express
siv
gag
gene
preclin
studi
vector
advanc
contribut
protect
efficaci
hiv
siv
gene
insert
addit
gag
vector
illustr
combin
approach
especi
incorpor
prime
improv
plasmid
dna
vaccin
focu
immun
respons
gene
product
interest
follow
boost
adrecombin
express
gene
product
shown
enhanc
replic
nonrepl
vaccin
vector
robertguroff
protect
efficaci
upon
move
studi
human
earli
clinic
trial
demonstr
nonrepl
adrecombin
hiv
vaccin
alon
combin
dna
safe
immunogen
lead
larg
scale
human
trial
discuss
later
review
recent
find
longterm
persist
replicationdefect
adrecombinantinduc
cell
mice
indic
recombin
ad
genom
transcript
activ
low
level
long
period
time
regard
nonrepl
recombin
exhibit
featur
replicationcompet
ad
mice
maintain
activ
effector
cell
well
central
memori
cell
extent
characterist
impact
vaccin
efficaci
subject
investig
whether
replic
adrecombin
exhibit
greater
persist
initi
robust
replic
vivo
also
requir
studi
extens
use
nonrepl
vector
gene
therapi
applic
requir
repetit
administr
reveal
host
immun
develop
vector
limit
use
life
vector
eventu
level
antivector
immun
reach
prevent
infect
therapeut
vector
henc
express
insert
gene
product
known
whether
preexist
vaccineinduc
vector
immun
would
decreas
effect
vaccin
need
administ
limit
number
time
nevertheless
view
high
preval
worldwid
peopl
altern
vector
develop
vaccin
vehicl
includ
ad
rare
serotyp
use
sequenti
primeboost
regimen
avoid
lessen
impact
preexist
immun
well
crossreact
ad
serotyp
nonhuman
ad
chimpanze
origin
engin
chimer
vector
hypervari
region
hexon
protein
exampl
target
ad
neutral
antibodi
replac
correspond
region
rare
ad
serotyp
addit
ad
vector
base
exhibit
gut
tropism
develop
may
prove
use
oral
mucos
vaccin
without
need
enter
coat
protect
stomach
acid
altern
ad
vector
requir
safeti
test
rel
immunogen
comparison
need
clearli
establish
overal
provid
flexibl
primeboost
regimen
focu
immun
respons
insert
gene
avoid
antivector
immun
induc
prior
immun
replicationcompet
ad
vector
share
common
featur
replicationdefect
vaccin
discuss
differ
delet
region
result
limit
clone
capac
kb
compar
replicationdefect
ad
vector
possess
advantag
howev
offset
limit
one
practic
dosespar
effect
estim
dosag
replic
adrecombin
base
safe
dose
licens
oral
wildtyp
vaccin
least
log
lower
nonrepl
recombin
current
test
clinic
trial
dosespar
effect
attribut
subsequ
replic
vaccin
vector
vivo
offer
power
practic
advantag
futur
manufactur
vaccin
would
need
produc
suffici
materi
worldwid
use
main
scientif
advantag
replic
adrecombin
mimick
natur
ad
infect
result
induct
cytokin
costimulatori
molecul
provid
potent
adjuv
effect
overal
replic
vector
provid
complet
immun
respons
includ
element
innat
immun
import
compon
rapid
respons
invad
organ
well
humor
cellular
mucos
immun
respons
basi
establish
safeti
record
oral
wildtyp
vaccin
use
year
us
militari
replicationcompet
vaccin
develop
base
vector
expect
equal
safe
date
preclin
studi
use
replic
adhiv
siv
recombin
shown
elicit
potent
cellular
immun
combin
envelop
subunit
boost
elicit
broad
antibodi
respons
possess
neutral
activ
also
function
properti
mediat
antibodydepend
cellular
cytotox
compar
studi
chimpanze
replic
nonrepl
adhiv
recombin
encod
ident
gene
product
illustr
greater
induct
cellular
immun
respons
replic
recombin
abil
prime
potent
antibodi
respons
replic
adsiv
recombin
primeproteinboost
regimen
induc
potent
durabl
protect
virul
siv
challeng
well
pathogen
shiv
isol
replic
adhiv
candid
vaccin
yet
test
clinic
approach
move
forward
phase
human
trial
adenoassoci
viru
aav
small
singlestrand
nonpathogen
dna
viru
contain
two
gene
replac
foreign
gene
leav
termin
itr
allow
high
level
express
insert
vector
infect
muscl
cell
provid
long
last
express
either
episom
integr
genom
form
nonenvelop
vector
aav
exhibit
physic
stabil
particular
resist
acid
suggest
potenti
use
oral
deliveri
product
vector
present
difficulti
howev
helper
function
must
provid
tran
requir
subsequ
purif
away
helper
viru
integr
vector
also
potenti
safeti
concern
although
recent
report
suggest
aav
integr
frequent
nake
dna
although
aav
serotyp
ubiquit
therefor
might
poorli
immunogen
target
popul
exhibit
prior
immun
altern
serotyp
avail
aav
type
particular
shown
exhibit
higher
tropism
mous
human
dendrit
cell
elicit
potent
cellular
humor
respons
mice
promis
studi
rhesu
macaqu
show
singl
high
dose
aav
encod
siv
gene
could
elicit
cellular
immun
respons
neutral
antibodi
protect
efficaci
also
observ
follow
siv
challeng
initi
phase
human
studi
aavbas
vaccin
encod
hiv
gag
proteas
delet
revers
transcriptas
gene
conduct
vaccin
prove
safe
minim
immunogen
posit
cell
respons
rate
group
receiv
highest
immun
dose
although
aav
vector
shown
elicit
potent
b
cell
respons
hivspecif
antibodi
observ
recent
studi
conduct
mice
reveal
pseudotyp
vector
encod
hiv
gag
gene
elicit
robust
cellular
respons
consist
mostli
effector
cell
quickli
contract
yield
central
memori
cell
possibl
mechan
might
explain
find
includ
littl
activ
innat
immun
insuffici
cell
help
cell
exhaust
follow
immun
vector
find
need
better
understood
order
take
full
advantag
aav
vector
system
alphavirus
develop
vaccin
vector
includ
venezuelan
equin
enceph
viru
vee
sindbi
viru
sin
semliki
forest
viru
sfv
veesin
chimera
spectrum
vaccin
applic
includ
hiv
also
rang
cancer
vaccin
altern
vaccinia
smallpox
vaccin
infecti
agent
parainfluenza
viru
alphavirus
singlestrand
positivesens
rna
virus
replic
cytoplasm
infect
cell
therefor
potenti
integr
host
genom
gener
circumv
safeti
concern
alphaviru
vector
engin
nonrepl
replicon
particl
structur
gene
product
delet
accommod
foreign
gene
kb
structur
protein
provid
tran
two
helper
transcript
lack
packag
signal
delet
structur
gene
provid
advantag
reduc
immun
vector
enabl
sequenti
immun
importantli
vector
natur
target
dendrit
cell
drain
lymph
node
transgen
express
high
level
lead
good
immun
respons
immunogen
enhanc
selfamplif
vector
rna
occur
doublestrand
rna
intermedi
stimul
activ
interferon
cascad
mimick
innat
immun
vector
also
induc
apoptosi
cell
type
therebi
lead
crossprim
recent
research
result
suggest
potenti
new
applic
alphaviru
vector
engin
secret
protein
encod
transgen
addit
design
express
heterolog
protein
surfac
infecti
viru
particl
notabl
phase
human
trial
vee
vectorbas
hiv
vaccin
conduct
trial
test
vee
express
hiv
clade
c
envelop
gag
nef
pol
gene
plan
start
combin
approach
involv
prime
veesin
replicon
encod
hiv
siv
gene
follow
boost
hiv
envelop
protein
elicit
cellular
immun
neutral
antibodi
result
significantli
lower
acut
viremia
follow
exposur
shiv
suggest
potenti
vector
explor
herpesviru
vector
use
extens
gene
therapi
applic
relat
central
peripher
nervou
system
larg
envelop
doublestrand
dna
virus
infect
varieti
tissu
type
also
target
mucos
surfac
therefor
advantag
elicit
mucos
immun
respons
vector
accommod
larg
foreign
gene
insert
bias
induct
cellular
respons
addit
activ
induct
proinflammatori
cytokin
induct
type
interferon
replicationcompet
incompet
vector
develop
replicationcompet
herpesviru
vector
advantag
mani
applic
persist
replicationdefici
hervesviru
vaccin
vector
also
induc
durabl
immun
respons
vector
type
previous
evalu
siv
rhesu
macaqu
model
protect
efficaci
follow
immun
vector
express
siv
env
nef
gene
weak
persist
antisiv
envelop
antibodi
elicit
along
rel
weak
sporad
cellular
immun
respons
nevertheless
follow
intrarect
challeng
pathogen
siv
two
seven
immun
macaqu
strongli
protect
third
show
diminish
chronic
viremia
provid
basi
continu
develop
herpesviru
vector
system
use
improv
replicationdefect
herpesviru
vector
engin
prolong
express
transgen
prevent
mhc
downregul
blockad
tap
peptid
transport
hsv
recombin
encod
siv
env
gag
revtatnef
gene
evalu
rhesu
macaqu
without
prior
prime
dna
vaccin
express
siv
gag
env
poltatnefvif
fusion
protein
contrast
earlier
studi
strong
cellular
respons
env
gag
elicit
togeth
antisiv
antibodi
readili
detect
elisa
possess
lowtit
neutral
activ
neutralizationsensit
siv
strain
follow
challeng
siv
modestli
reduc
acut
phase
viremia
observ
comparison
histor
control
anim
protect
extend
chronic
phase
infect
whether
vector
prove
effect
combin
cytokin
adjuv
vector
booster
immun
envelop
protein
await
futur
studi
use
vector
base
measl
viru
mv
neg
singlestrand
rna
viru
rel
new
hiv
vaccin
arena
yet
recombin
encod
numer
viral
gene
construct
includ
hepat
b
mump
west
nile
viru
sever
acut
respiratori
syndrom
coronaviru
sar
mv
vector
present
sever
featur
would
advantag
hivaid
vaccin
live
attenu
mv
vaccin
elicit
lifelong
immun
cellular
humor
immun
persist
year
abil
viru
infect
antigen
present
dendrit
cell
macrophag
may
relat
properti
viru
replic
cytoplasm
thu
preclud
integr
nucleocapsid
mv
helic
structur
vector
accommod
larg
gene
insert
kb
viru
exhibit
genet
stabil
follow
multipl
passag
vitro
mv
recombin
express
hiv
envelop
glycoprotein
elicit
high
titer
antibodi
hiv
envspecif
cell
follow
singl
inject
notabl
antibodi
possess
neutral
activ
hiv
immun
strain
well
sever
heterolog
isol
similar
result
report
follow
vaccin
mice
human
mhc
class
mv
administ
million
children
view
induct
persist
immun
one
might
anticip
use
vector
subsequ
recombin
vaccin
might
compromis
prior
immun
howev
macaqu
immun
mv
therebi
develop
persist
mv
antibodi
still
exhibit
hightit
antibodi
hiv
envelop
follow
two
immun
year
later
mvhivenv
recombin
discuss
refer
revaccin
individu
alreadi
immun
mv
vaccin
led
boost
mv
antibodi
titer
moreov
matern
antimv
antibodi
prevent
develop
cellular
immun
respons
mv
infant
immun
year
follow
birth
expect
therefor
adult
might
still
abl
immun
differ
viral
infect
use
mv
recombin
view
potenti
mv
vector
concept
need
evalu
addit
adenoviru
vector
poxviru
vector
among
heavili
exploit
vaccin
develop
use
larg
attribut
overwhelm
success
vaccinia
viru
vaccin
erad
smallpox
vacciniahiv
recombin
evalu
human
clinic
trial
howev
larg
concern
use
replic
vector
immun
compromis
individu
safer
nonrepl
poxviru
vector
focu
extens
develop
includ
modifi
vaccinia
viru
ankara
mva
replic
defici
due
loss
approxim
genom
upon
repetit
serial
passag
chick
embryo
fibroblast
nyvac
deriv
copenhagen
strain
vaccinia
render
replic
incompet
specif
engin
delet
avipox
vector
canarypox
alvac
fowlpox
fpv
latter
natur
restrict
growth
avian
cell
infect
mammalian
cell
replic
mammalian
poxvirus
doublestrand
dna
genom
approxim
kb
avian
poxvirus
kb
larg
genom
allow
insert
kb
foreign
dna
gene
product
express
high
level
gener
result
potent
cellular
immun
respons
attenu
poxvir
recombin
deliveri
vaccin
antigen
among
earliest
use
preclin
hivsiv
vaccin
studi
shown
immunogen
elicit
protect
immun
siv
rhesu
macaqu
model
interest
hiv
vaccin
field
stimul
report
prime
multigen
dna
vaccin
follow
boost
recombin
mva
vector
express
hiv
env
siv
gag
pol
protein
led
signific
protect
rhesu
macaqu
shiv
challeng
level
protect
observ
togeth
protect
obtain
later
studi
use
similar
primeboost
regimen
compos
dna
follow
adrecombin
led
design
plethora
combin
vaccin
approach
stimul
numer
human
trial
poxvirushiv
recombin
vaccin
avipox
vector
special
interest
smallpox
erad
program
led
signific
prior
immun
worldwid
vaccinia
relat
mva
nyvac
vector
yet
immun
respons
crossreact
alvac
fpv
vector
clinic
trial
alvachiv
recombin
shown
safe
howev
elicit
modest
hivspecif
cellular
immun
respons
fact
phase
studi
multigen
alvachiv
vaccin
candid
follow
boost
recombin
fail
elicit
ctl
frequenc
healthi
volunt
evalu
ifng
secret
therefor
advanc
proofofconcept
trial
design
investig
correl
protect
immun
nevertheless
relat
phase
iii
efficaci
trial
alvac
recombin
express
hiv
env
clade
b
e
togeth
gag
pol
follow
boost
clade
b
e
underway
thailand
whether
inclus
vaccinia
gene
earlier
alvec
vector
intend
improv
antigen
express
present
may
instead
inhibit
apoptosi
ifninduc
effect
therebi
influenc
antigen
present
limit
crossprim
may
abl
discern
current
phase
iii
trial
alvac
vector
lack
two
gene
flexibl
varieti
poxviru
vector
prompt
compar
studi
among
vector
order
narrow
potenti
candid
human
studi
vitro
studi
alvac
mva
recombin
contain
ident
hiv
gene
insert
reveal
apoptosi
induct
similar
recombin
vector
recombin
mva
express
greater
level
encod
antigen
alvac
recombin
primarili
due
longer
durat
express
notabl
mva
express
antigen
human
dendrit
cell
elicit
enhanc
cell
stimul
vitro
find
bear
greater
immunogen
mva
vector
exhibit
vivo
comparison
modest
respons
induc
alvac
vector
clinic
trial
ident
nyvac
mva
recombin
also
recent
compar
mice
vector
express
high
level
gene
product
differ
observ
regard
cytokin
express
breadth
respons
microarray
analysi
mva
enhanc
express
sever
proinflammatori
cytokin
contrast
nyvac
howev
nyvacmva
combin
strategi
initi
prime
nyvac
recombin
follow
mva
recombin
gave
broadest
cellular
immun
respons
contrast
weaker
respons
nyvac
recombin
booster
immunogen
may
reflect
antivector
immun
elicit
significantli
smaller
mva
vector
case
immun
respons
would
focus
smaller
number
common
gene
present
nyvac
mva
lead
greater
inhibit
nyvac
booster
immunogen
increas
breadth
cellular
immun
elicit
nyvac
vector
could
link
greater
induct
apoptosi
lead
greater
abund
antigen
avail
crossprim
address
differ
effect
headtohead
comparison
would
need
human
trial
studi
sequenti
immun
strategi
use
vaccinia
fpv
mva
recombin
recent
conduct
rhesu
macaqu
heterolog
primeboost
approach
use
mvafpv
vaccinia
fpv
gave
equival
immun
respons
greater
elicit
homolog
mvamva
approach
howev
follow
challeng
shiv
similar
level
memori
cell
respons
observ
group
immun
monkey
along
similar
protect
efficaci
result
may
reflect
rel
eas
achiev
viremia
control
follow
shiv
challeng
overal
inadequaci
discrimin
subtl
differ
immun
respons
result
suggest
select
best
vector
ultim
need
determin
human
clinic
trial
vesicular
stomat
viru
vsv
compar
new
addit
group
replicationcompet
viral
vaccin
vector
knowledg
manipul
neg
singlestrand
rna
genom
rel
recent
acquir
howev
report
rose
et
al
signific
protect
shiv
challeng
follow
two
sequenti
immun
rhesu
macaqu
recombin
vsv
vector
express
hiv
envelop
siv
gag
vector
becam
promin
vaccin
candid
addit
promis
hivaid
vaccin
field
shown
effect
vaccin
vehicl
lethal
viral
infect
ebola
marburg
virus
nonhuman
primat
pandem
influenza
mice
advantag
vector
includ
replic
cytoplasm
thu
avoid
integr
host
dna
high
level
transgen
express
due
shut
host
mrna
translat
eas
product
due
rapid
life
cycl
limit
preexist
immun
popul
abil
administ
mucos
natur
host
vsv
infect
insect
livestock
rare
case
viru
transmit
human
asymptomat
caus
mild
symptom
nevertheless
replic
vector
vigor
investig
safeti
vsv
found
neurovirul
rodent
also
nonhuman
primat
follow
direct
intracrani
inocul
although
intranas
administr
recombin
vsv
macaqu
result
spread
central
nervou
system
intrathalam
inocul
result
sever
neuropatholog
result
vector
aggress
attenu
meet
safeti
criteria
time
effort
increas
immunogen
weaken
vector
explor
includ
increas
transgen
express
shift
posit
transgen
end
genom
end
coexpress
immun
modul
target
dendrit
cell
combin
strategi
vector
deliveri
system
fact
benefit
prime
rhesu
macaqu
plasmid
dna
express
siv
gag
togeth
dna
encod
follow
intranas
boost
vsv
recombin
express
hiv
env
siv
gag
result
enhanc
cellular
humor
immun
respons
reduc
viremia
follow
challeng
shiv
compar
macaqu
receiv
vsv
recombin
whether
attenu
vector
meet
safeti
criteria
whether
nonrepl
vsv
vector
develop
fulli
order
continu
exploit
attract
featur
viral
vector
determin
outcom
futur
studi
nonrepl
vsv
vector
lack
vsv
glycoprotein
essenti
infect
design
vaccin
hepat
c
viru
review
avail
viral
vaccin
vector
addit
omit
nake
dna
bacteri
vector
nevertheless
appar
array
choic
vector
vaccin
develop
success
specif
vaccin
applic
reflect
larg
part
vector
select
first
consider
choos
vector
whether
use
prophylact
therapeut
applic
peopl
alreadi
infect
infecti
agent
hiv
benefit
therapeut
vaccin
may
outweigh
risk
attribut
vector
contrast
prophylact
vaccin
intend
healthi
peopl
adult
also
children
infant
therefor
safeti
paramount
import
regard
hiv
vaccin
real
possibl
potenti
vaccine
target
popul
alreadi
hivposit
perhap
immun
suppress
make
safeti
viral
vector
great
import
vector
select
also
requir
thorough
understand
biolog
infecti
agent
vaccin
develop
knowledg
cours
result
diseas
mode
transmiss
infecti
agent
impact
vector
choic
moreov
natur
recoveri
diseas
often
highlight
immun
respons
correl
control
erad
infecti
agent
provid
crucial
inform
regard
type
immun
respons
desir
cellular
mucos
andor
humor
alreadi
allud
review
regard
antivector
immun
initi
definit
target
popul
vaccin
essenti
select
vector
adult
vaccine
may
alreadi
heavili
expos
particular
viral
vector
therefor
exhibit
high
level
antivector
immun
infant
may
acquir
matern
antibodi
potenti
vaccin
vector
preclud
effect
vaccin
recent
report
seropreval
studi
sever
potenti
ad
vector
differ
serotyp
reveal
strong
agedepend
neutral
antibodi
infant
exhibit
low
titer
howev
titer
increas
rapidli
age
nearli
individu
neutral
titer
situat
vaccin
infant
vaccin
might
quit
effect
wherea
vaccin
adult
would
expect
result
much
lower
respons
rate
practic
featur
import
scientif
one
capac
viral
vector
foreign
dna
must
suffici
gene
insert
one
gene
product
need
express
vector
larg
capac
would
advantag
rather
use
multipl
recombin
manufactur
strategi
abl
provid
vaccin
use
million
peopl
worldwid
also
import
consider
system
larg
scale
product
must
avail
viral
recombin
must
genet
stabl
order
maintain
integr
multipl
passag
order
reach
desir
quantiti
vaccin
materi
addit
global
use
vaccin
impli
use
develop
world
cold
storag
sophist
equip
vaccin
administr
alway
avail
therefor
vaccin
physic
stabl
requir
freez
even
refriger
prefer
needleless
vaccin
administ
oral
focu
vector
use
hiv
vaccin
develop
formid
challeng
vaccinologist
area
research
requir
consider
vaccin
approach
upon
infect
hiv
quickli
integr
host
dna
result
essenti
lifelong
infect
henc
optim
vaccin
elicit
steril
immun
prevent
infect
altogeth
type
immun
gener
provid
antibodi
rout
infect
hiv
primarili
across
mucos
surfac
impli
mucos
immun
import
compon
success
vaccin
viru
highli
mutabl
suggest
broad
immun
respons
requir
protect
addit
broadli
reactiv
neutral
antibodi
immun
highli
conserv
cellular
compon
would
also
desir
aid
worldwid
epidem
vaccin
use
global
necessari
initi
hiv
vaccin
candid
base
inactiv
viru
viral
compon
ineffect
attenu
hiv
vaccin
inher
unsaf
vector
vaccin
becam
strategi
choic
present
review
replic
nonrepl
vector
vaccin
particularli
time
hiv
vaccin
research
recent
withdraw
lead
replicationdefect
adhiv
recombin
vaccin
candid
phase
iib
clinic
trial
prompt
reevalu
current
approach
field
human
trial
question
address
issu
whether
vaccin
design
elicit
cell
immun
would
protect
hiv
infect
andor
would
help
control
diseas
progress
individu
becam
infect
neither
outcom
achiev
present
known
whether
vector
vaccin
simpli
induc
suffici
cell
immun
whether
elicit
wrong
type
cellular
immun
whether
concept
cell
immun
alon
would
suffici
protect
hiv
incorrect
answer
first
two
question
emerg
data
trial
undergo
analysi
evalu
immunogen
vaccin
investig
induc
quantiti
qualiti
cellular
immun
desir
contrast
answer
third
question
probabl
known
success
vaccin
achiev
immun
correl
protect
identifi
howev
concept
sole
cell
base
vaccin
would
protect
hiv
infect
probabl
overli
optimist
consider
kinet
infect
time
necessari
memori
cell
encount
antigen
replic
differenti
effector
cell
migrat
sourc
infect
provid
immun
protect
failur
cell
base
vaccin
modul
hiv
viral
load
follow
infect
unexpect
result
howev
may
relat
level
system
mucos
cellular
immun
elicit
type
immun
cell
induc
yet
disappoint
outcom
trial
mean
cellular
compon
futur
vaccin
necessari
suggest
suffici
compon
probabl
essenti
includ
antienvelop
antibodi
mucos
immun
engag
innat
immun
system
short
approach
bring
compon
immun
system
play
halt
phase
iib
trial
also
mean
nonrepl
vector
longer
use
whether
singl
vaccin
vector
could
meet
requir
doubt
like
mixtur
vaccin
compon
ultim
compris
success
vaccin
nevertheless
key
start
point
select
replic
vaccin
vector
live
attenu
siv
vaccin
demonstr
highli
effect
protect
virul
siv
challeng
nonhuman
primat
although
use
similarli
attenu
hiv
vaccin
peopl
possibl
safeti
concern
yet
featur
live
attenu
approach
probabl
simul
close
use
replic
vector
publish
previous
replic
vector
stimul
immun
system
similarli
natur
infect
characterist
featur
includ
prolong
express
insert
gene
therefor
favor
persist
immun
induct
proinflammatori
cytok
costimulatori
molecul
function
adjuv
vivo
replic
provid
greater
effect
dose
greater
immunogen
natur
target
accord
cell
tissu
tropism
compon
immun
system
engag
adapt
well
innat
select
replic
vector
mucos
tropism
would
addit
lead
induct
immun
mucos
effector
site
idea
initi
prime
immun
replic
recombin
vector
import
hiv
vaccin
support
report
boost
mucos
immun
inactiv
polioviru
vaccin
depend
first
immun
live
oral
polioviru
vaccin
administr
inactiv
vaccin
first
less
effect
elicit
strong
mucos
respons
concept
need
test
appropri
anim
model
howev
suggest
follow
initi
prime
replic
vector
either
replic
nonrepl
vaccin
vector
could
use
booster
immunogen
combin
approach
use
sequenti
immun
homolog
vector
perhap
differ
subtyp
avoid
vectorinduc
immun
heterolog
vector
may
highli
effici
focus
immun
respons
insert
gene
product
thu
enhanc
overal
immun
respons
vector
vaccin
design
elicit
cellular
immun
respons
vector
prime
provid
cell
help
b
cell
respons
order
induc
broad
potent
antibodi
booster
inocul
protein
antigen
gener
necessari
altern
viral
vector
alphaviru
engin
elicit
potent
antibodi
respons
might
prove
use
altern
overal
term
compon
vaccin
deliveri
strategi
hiv
compos
initi
prime
replic
vector
mucos
tropism
boost
cellular
mucos
immun
homolog
heterolog
replic
nonrepl
vector
boost
protein
vector
compon
design
elicit
antibodi
may
best
chanc
effect
hivaid
vaccin
scheme
take
advantag
innat
immun
system
amplifi
adapt
immun
respons
made
initi
antigen
exposur
upon
immun
ultim
elicit
strong
cellular
humor
mucos
immun
target
antigen
addit
signific
challeng
howev
must
still
met
includ
identif
best
combin
gene
insert
vector
vaccin
design
protein
booster
immunogen
elicit
broadest
potent
neutral
antibodi
possibl
